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Abstract
Obesity is thought to cause ill health due to the biological strain that excess fat has on physiological function. In a population-based sample of 3,609 older English adults we tested an alternative explanation: that the pervasive discrimination experienced by individuals with excess weight may in part explain why obesity is associated with subsequent multi-system physiological dysregulation, measured via clinical indicators of cardiovascular, metabolic, and immune function. We found that obesity and perceived weight discrimination both predicted an increase in physiological dysregulation from baseline to follow-up four years later. Perceived discrimination because of body weight experienced by individuals with obesity explained over a quarter of the prospective association between obesity and a deterioration in biomarkers of health status. These findings highlight the possibility that the stigma experienced by individuals with obesity may play an important role in explaining the obesity-related disease burden. 











Introduction
The prevalence of obesity continues to rise globally and has been paralleled by dramatic increases in related health comorbidities, disability, and reduced quality of life (GBD 2015 Obesity Collaborators, 2017). Relations between obesity and critical health outcomes including diabetes, hypertension, cardiovascular disease, and premature mortality are well documented (e.g. Guh et al., 2009). Until recently (Hunger & Major, 2015; Robinson, Sutin, & Daly, 2017; Tomiyama et al., 2018) the health damaging effects of obesity have been assumed to result from the direct impact of excess adipose tissue on a series of biological processes including insulin resistance, glucose intolerance, raised blood pressure, low-grade inflammation, and dyslipidaemia (Kahn, Hull, & Utzschneider,  2006; Van Gaal, Mertens, & De Block, 2006). However, there are other plausible mechanisms that may explain why obesity is associated with deterioration of physiological functioning and biological ill health, one of which we focus on here; the widespread discrimination and stigma experienced by individuals living with obesity.  
Negative attitudes towards persons with obesity are widespread in contemporary society as evidenced by disparaging media portrayals (e.g. unpopular, unattractive) and negative beliefs (e.g. incompetent, lazy) held by the public and healthcare professionals (Pearl, 2018; Puhl & Heuer, 2009). Such weight-biased stereotypes may perpetuate the social devaluation, denigration, and unjust treatment of people with obesity identified within educational, employment, and healthcare settings (Pearl, 2018). Perhaps because of this, in recent years there has been a marked increase in those reporting unfair treatment based on their body weight, otherwise known as perceived weight discrimination (Andreyeva, Puhl, & Brownell, 2008). This is particularly concerning because weight-based discrimination has been conceptualized as a pervasive social stressor that may connect obesity to poor mental and physical health (Daly et al., 2017; Hunger & Major, 2015; Tomiyama, 2014). 
Abundant evidence has linked weight-based discrimination to a host of significant psychosocial consequences including increased risk of loneliness, diminished self-worth, depression, and anxiety (Hatzenbuehler, Keyes, & Hasin, 2009; Robinson et al., 2017; Sutin et al., 2016b). In addition to these damaging mental health effects, recent findings have tied weight discrimination to unfavorable physical health outcomes including weight gain, declines in subjective health and mobility, greater disease burden, and premature mortality (Sutin et al., 2015; Sutin, Stephan, & Terracciano, 2015; Schafer & Ferraro, 2011). Prominent theoretical models have suggested that heightened psychological and physiological stress responses to perceived weight discrimination may explain why these experiences are so closely related to poor physical health, but formal testing of this proposition has been limited (Pascoe & Smart Richman, 2009; Tomiyama, 2014).  
Experimental studies have shown that exposure to weight stigmatizing content can induce acute increases in autonomic system and hypothalamic-pituitary-adrenal (HPA) activation as gauged by raised blood pressure (Major, Eliezer, Rieck, 2012) and increased cortisol reactivity (Himmelstein, Incollingo Belsky, & Tomiyama, 2015; Schvey, Puhl, & Brownell, 2014). Short term laboratory studies also suggest that the stigma and stress attached to feeling overweight may compromise self-regulation leading to increased calorific intake (Vartanian & Porter, 2016). Observational studies have also linked experiences of weight-based discrimination to overeating and unhealthy eating (e.g. Sutin, Robinson, Daly, & Terracciano, 2016) and elevated hair cortisol levels (Jackson, Kirschbaum, & Steptoe, 2016), an indicator of prolonged stress exposure. Taken together, these studies provide initial evidence to suggest that weight stigma may impact cardiovascular and neuroendocrine function and appetite regulation potentially generating pronounced downstream physiological effects across multiple bodily systems (Tomiyama, 2014; Epel, Lapidus, McEwen, & Brownell, 2001). Indeed, recent evidence has linked sustained unfair treatment based on body weight to increased physiological dysregulation, as gauged by raised inflammation levels (Sutin, Stephan, Luchetti, & Terracciano, 2014), impaired glycemic control (Potter et al., 2015), and lipid/metabolic dysregulation (Vadiveloo & Mattei, 2017). 
Despite this evidence, it is not yet known whether the widespread experience of weight-based discrimination among people living with obesity explains why obesity produces long-term changes in objective indicators of human health. To date, studies examining the negative health effects of unfair treatment based on body weight have tended to statistically adjust for BMI, thus emphasizing that weight-based discrimination may have adverse effects over and above those of obesity. A small number of studies have demonstrated that weight-based discrimination and concerns about weight mediate the cross-sectional association between body weight and subjective health (e.g. Hunger & Major, 2015; Jackson, Beeken, & Wardle, 2015). However, such studies rely on self-reported measures which are prone to bias and their cross-sectional nature cannot rule out the distinct possibility of reverse causality.
The aim of the current study was therefore to first to examine the relationship between obesity and longitudinal increases in biological ill health over four years, in the form of physiological dysregulation. We operationalized dysregulation using a combination of objective clinical indicators of cardiovascular, inflammatory, and lipid/metabolic dysregulation considered indicative of allostatic load (Juster, McEwen, & Lupien, 2010; Hampson, Goldberg, Vogt, Hillier, & Dubanoski, 2009). Allostatic load theory suggests that such dysregulation measures can capture the downstream biological toll of repeated attempts to adapt to a chronic stressor, such as weight discrimination, which over time may produce an accumulation of “wear-and-tear” across multiple physiological systems (Seeman, McEwen, Rowe, & Singer, 2001). More importantly, we also aimed to use our integrative measure of biological risk to test whether the physiological consequences of obesity may be, at least in part, attributable to the stress of weight discrimination. Specifically, for the first time we tested whether perceived weight-based discrimination forecasts longitudinal changes in physiological dysregulation, and then examined whether these discriminatory experiences mediate the prospective association between obesity and dysregulation in a large population-based study of older English adults. 

Methods
Participants
	This study draws on data from the English Longitudinal Study of Ageing (ELSA), an ongoing, prospective observational study to study the health and ageing of older (≥ 50 years), non-institutionalized men and women in England. The ELSA cohort was recruited from three waves of the Health Survey for England (1998, 1999, and 2001), an annual, nationally representative, cross-sectional household survey, based on a stratified random sample of English households. Initial participants were recruited if they were born before March 1, 1952 and were interviewed as part of wave 1 in 2002/2003. The sociodemographic characteristics of the ELSA sample have been shown to align broadly with the results of the national census. Further information on the ELSA measures and sampling procedures is detailed elsewhere (Steptoe, Breeze, Banks, & Nazroo, 2012). Since 2002 participants have been followed up with face-to-face interviews in participant’s own homes every two years with clinical assessments including blood sample analysis in alternate ELSA waves every four years. To maintain sample size and representativeness ‘refreshment samples’ have been added as part of each wave since 2006. Participants provided informed consent to take part in ELSA, and ethical approval was obtained from the London Multicentre Research Ethics Committee.
For the purposes of the current study, the baseline sample is those with available height and weight measurements from the wave 4 clinical assessment (2008-2009). We examined longitudinal change in physiological dysregulation over four years from baseline/wave 4 to follow-up/wave 6 (2012-2013). Experiences of weight discrimination were assessed as part of the wave 5 (2010-2011) interview. We restricted our sample to those with available data on: baseline BMI, weight discrimination, and physiological dysregulation at baseline and follow-up (see Table 1 for sample characteristics). Of the 6,121 participants with baseline/wave 4 BMI and dysregulation data, 848 did not have information on weight-based discrimination from wave 5 (2010-2011), and 1,577 were excluded because they did not have information on physiological dysregulation levels at follow-up and 87 participants were missing additional covariate or survey weight data. There was no difference in gender or obesity between those with baseline but not follow-up data. However, participants included in the final analytic sample (N = 3,609) were more likely to be younger, white, to have greater household wealth, and were less likely to have been diagnosed with lung disease or to have high levels of depressive symptoms (all p < 0.01). Those included in the sample also had lower levels of baseline physiological dysregulation. 
We used inverse probability weighting to account for potential bias due to selective attrition. Specifically, we used all baseline covariate data to estimate each participant’s predicted probability of retention at follow-up from a logistic regression model. We then calculated weights that were inversely proportional to the probability of retention. Applying these weights to our analyses provided a correction for the baseline differences observed between participants lost to follow-up and those retained in the analytic sample. For example, those with baseline characteristics associated with a reduced likelihood of retention (e.g. low wealth) were assigned larger weights to compensate for the underrepresentation of this group in the final sample. These weights were combined with the ELSA wave 4 clinical assessment weights to take account of baseline non-response and more accurately represent the characteristics of the population.
Measures												
Anthropometry. Objective anthropometric measurements were taken by trained nurses as part of the wave 4 clinical assessment. Weight without shoes and in light clothing was recorded to the nearest 0.1 kg using the Tanita THD-305 portable electronic scales. A portable stadiometer was used to measure standing height without shoes to the nearest millimetre. Each participant’s BMI was calculated as weight [(in kilograms) / height (in meters)2] and obesity was defined a those with BMI levels ≥ 30 kg/m2. 

Perceived Weight Discrimination. Weight-based discrimination was measured using a version of the perceived everyday experiences with discrimination scale (Williams, Yu, Jackson, & Anderson, 1997) administered in ELSA. Participants were firstly asked, “In your day-to-day life, how often have any of the following things happened to you?” Participants then rated how frequently they encountered a set of five discriminatory experiences (e.g. “you are treated with less respect or courtesy”, “you are threatened or harassed”) on a scale from 1 (Almost every day) to 6 (Never).  Participants then identified the reason(s) they were treated unfairly from a list of options that included weight. Perceived weight discrimination was defined as those who reported any form of discrimination and attributed this to their weight. 

Physiological Dysregulation Index. As part of the wave 4 and wave 6 follow-up assessments participants were visited in their homes by a trained nurse who collected biomarker data. In line with prior research (e.g. Daly, Robinson, & Sutin, 2017; Hampson et al., 2009) we drew on biomarkers of cardiovascular, immune, and metabolic system functioning to generate a composite index of physiological dysregulation indicative of allostatic load (Seeman et al., 2001). Cardiovascular measures were systolic and diastolic blood pressure and resting pulse rate. Inflammation levels were assessed using C-reactive protein and white blood cell count levels. Lipid and metabolic dysregulation were assessed with: the ratio of total blood cholesterol to high-density lipoprotein cholesterol, triglyceride levels, and glucose and glycated hemoglobin levels (hemoglobin A1c). 
As part of the clinical assessment, nurses followed standardized procedures to assess participants’ resting, seating blood pressure and pulse rate from the right arm using the Omron HEM-907 oscillometric blood pressure monitor. Three readings were taken at one-minute and average levels from the last two readings were used in the current analysis. Blood samples were drawn from those who gave consent except for participants with clotting or bleeding disorders, a history of fits/convulsions, or those on anticoagulant medications (e.g. Warfarin). Blood samples were analyzed following the technical specifications and quality control guidelines outlined in the Health Survey of England technical report (Craig, Deverill, & Pickering, 2006). 
We employed the z-score method (Hampson et al., 2009; Juster et al., 2010) which involves averaging the computed z-scores for each biomarker in order to place all biomarkers onto a common scale and generate a single continuous summary score. Z-scores have been used in a broad set of studies though they appear less frequently than traditional count-based scores in the allostatic load literature (Hampson et al., 2009; Juster et al., 2010; Seplaski, Goldman, Glei, & Weinstein, 2005). The latter are calculated by summing the number of biomarkers for which an individual scores above a high-risk percentile threshold of biomarker values (e.g. upper 25th percentile) at a given time-point. Such count-based formulations are insensitive to mean-level changes in dysregulation levels over time.  Z-scores can be easily integrated into longitudinal analysis and have shown equivalent or superior performance to count-based scores in predictive models (Seplaski et al., 2005). We therefore combine biomarker z-scores to produce a summary score that captures the full continuum of biological risk associated with multisystem physiological dysregulation.
In order to conduct longitudinal analyses biomarker z-scores must be calculated across both time points together to ensure changes over time are retained. We followed this approach and to maximize the sample size we included ELSA participants if they provided data on at least three-quarters of the biological measures and remaining missing observations (< 6% of cases) were replaced with mean imputation. Individual biomarker z-scores were then averaged to generate a normally distributed physiological dysregulation index which was restandardized across both time points in order to retain longitudinal changes and produce an index with a mean of 0 and standard deviation of 1. 
In keeping with the allostatic load literature (Juster et al., 2010) we refer to our outcome measure as an index rather than a scale. This index taps a broad set of biomarkers in order to assess cumulative dysregulation across multiple biological systems (Seeman et al., 2001). Individual biomarkers are not assumed to be empirically correlated when constructing a cumulative index (Streiner, 2003). We observed an average correlation of 0.51 between the individual biomarkers and the overall index (see Table S1) and the test-retest reliability for the physiological dysregulation index was 0.68 (r(3607) = 0.68, p < .01). 

Covariates. We included controls for age, sex, ethnicity (white vs. non-white), whether the participant holds a degree level qualification, and overall household wealth (net non-pension wealth, adjusted to account for household size and converted to quintiles to remove skewness). We also adjusted for whether participants were taking medication to treat high blood pressure or diabetes, injecting insulin, or receiving treatment with cholesterol-reducing agents (e.g., statins) and diagnosis of a range of health conditions at baseline. Specifically, we included 19 variables assessing whether participants had been diagnosed with each of the following health conditions: high blood pressure, angina, congestive heart failure, myocardial infarction, arrhythmia, heart murmur, diabetes or high blood sugar, stroke, high cholesterol, lung disease, asthma, arthritis, osteoporosis, cancer, psychiatric condition, glaucoma, diabetic retinopathy, macular degeneration, and cataracts. Finally, we included a control for depressive symptoms assessed using a validated eight-item version of the Center for Epidemiology Depression Scale (CES-D; Turvey, Wallace, & Herzog, 1999). The CES-D uses a yes/no response format to assess feelings during the past week (e.g. “felt sad”, “could not get going”) and responses are summed to produce a total sum score ranging from 0 to 8 (M = 1.39, SD = 1.94; Cronbach’s α = 0.82) with higher scores indicating greater depressive symptoms. 

Analytic Strategy
	Our analyses aimed to: (i) estimate the association between obesity and subsequent dysregulation, (ii) test whether perceived weight discrimination predicted physiological dysregulation over and above initial obesity, and (iii) assess whether our measure of perceived weight discrimination may mediate part of the association between obesity and physiological dysregulation. We controlled for demographic characteristics, medication usage, health conditions, and depressive symptoms in all models. As a preliminary test of our study predictions we first examined the predicted associations without including baseline dysregulation as a covariate. Next, we turned our attention to the relationship between obesity, weight discrimination, and changes in dysregulation over time in order to provide a more stringent test our main study hypotheses.
	Latent change score (LCS) analysis. The LCS approach allows change to be explicitly modelled within a two-wave time series. As such, in the current study it was possible to identify increases or decreases in dysregulation levels from baseline to follow-up, and to estimate whether obesity and/or weight discrimination predicted this change. In the LCS model change in physiological dysregulation was rendered explicit by constraining baseline (T1) and follow-up (T2) dysregulation to be identical (i.e. by fixing the autoregression path to unity) and including a latent change score ( PHYS) with a factor loading fixed to 1 that captures the residual variance in dysregulation at follow-up (see Figure 1 for the model constraints imposed). Finally, we include a regression parameter β that accounts for the association between initial physiological dysregulation and the change score ( PHYS). 
Having tested whether an association exists between obesity and longitudinal change in dysregulation (total effect; path c) we conducted a series of tests to establish that the preconditions for successful mediation were present, as illustrated in Figure 1. Specifically, we tested whether (i) the independent variable (obesity) was associated with the mediator (perceived weight discrimination; path a) in a model that included baseline physiological dysregulation and covariates, and (ii) whether the mediator, weight discrimination, predicted longitudinal change in physiological dysregulation over the study period (path b) in a fully adjusted model. Where the conditions for mediation were present, a formal test of the significance levels of the potential indirect effect was conducted. To avoid biased standard errors and statistical significance levels due to unspecified non-constant error variance we estimated robust standard errors in all regression models. 

	We also re-estimated our LCS models in a series in robustness tests. First, we tested whether the same pattern of results was observed when: (i) a continuous BMI measure was examined rather than a dichotomous obesity indicator, or (ii) when waist circumference was used as an alternative measure of adiposity. We also tested whether the main study findings were moderated by participant gender. Next, we tested whether the association between weight discrimination and subsequent dysregulation was observed when more comprehensive controls for initial adiposity were included (i.e. adjusting for baseline waist circumference in addition to baseline BMI). Finally, we assessed the link between perceived weight discrimination and changes in dysregulation levels for each biological indicator individually. 

Results
	Descriptive statistics for basic demographic and baseline characteristics are shown in Table 1. The mean age of the sample was 64.78 (SD = 9.24), 52.7% were female, and 96.2% reported their ethnicity as white. The mean BMI of the sample was 28.22 (SD = 5.05) and the prevalence of obesity was 31% at baseline. In total, 13% of those in the obese group reported weight discrimination compared to 0.8% in the remainder of the sample (OR = 18.90, 95% CI = 9.92–35.99, p < 0.01).  Table S2 presents data on the prevalence of chronic conditions and medication usage. A substantial portion of the sample had been diagnosed with high blood pressure (39.4%), high cholesterol (35%), and arthritis (36.6%) and were taking blood pressure medication (29%) and cholesterol lowering medication (20.6%).  Table S3 details the correlations between all variables included in our main analyses. Age was positively correlated with physiological dysregulation whereas being female, white, and holding a degree were all negatively associated with dysregulation. Household wealth was negatively correlated with physiological dysregulation at baseline and follow-up (average r = -.20). Obesity at baseline was positively correlated with physiological dysregulation at both time-points (average r = .30) as was weight discrimination (average r = .16) and depressive symptoms (average r = .13).  The presence of diabetes (r = .26) and use of diabetes medication (r = .24) were both positively linked to dysregulation across waves. 
	In an initial regression model that did not adjust for baseline dysregulation levels, we found that obesity predicted physiological dysregulation at follow-up (d = .45, 95% CI = [.37, .53], p < .01). Perceived weight discrimination also predicted raised levels of dysregulation at follow-up (d = .34, 95% CI = [.13, .54], p < .01) in this model. Further, the inclusion of weight discrimination reduced the association between obesity and dysregulation by 9% (d = .41, 95% CI = [.33, .50], p < .01). Mediation analyses confirmed the presence of a statistically significant indirect effect of weight discrimination explained 9% of the overall association between obesity and physiological dysregulation (d = .04, 95% CI = [.02, .07], p < .01). To build on this initial evidence we next examined the interlinkages between obesity, weight discrimination, and changes in dysregulation over time. 

Latent Change Score Model
There was a heterogenous pattern of longitudinal change across the biomarkers examined, as detailed in Table S1. The majority of biomarkers did not change markedly over the study period. In contrast, glucose increased notably (from 4.9 to 5.4 mmol/L), and there was evidence of decline in triglycerides (from 1.8 to 1.5 mmol/L) and the total to HDL cholesterol ratio declined (from 3.8 to 3.5). After converting all biomarkers to z-scores and producing a combined index we found that on average the unconditional mean-level change in physiological dysregulation (PHYS in Figure 1) was positive (d = 0.03) but not significantly different from zero. 
	Obesity at baseline forecasted a .09 SD increase in physiological dysregulation from baseline to follow-up (d = .09, 95% CI = [.02, .16], p < .01). We also found that perceived weight discrimination predicted a 0.23 SD increase in physiological dysregulation over the study period (d = .23, 95% CI = [.07, .40], p < .01).  We therefore found evidence for a longitudinal association between obesity and subsequent physiological dysregulation (total effect; path c), that obesity was associated with high levels of weight discrimination (mediation path a) and that weight discrimination predicted increased physiological dysregulation over time (mediation path b), as illustrated in Figure 1. Further, the link between obesity and increased dysregulation was no longer statistically significant after the inclusion of weight discrimination in the regression model (total effect; path c: d = .09, 95% CI = [.02, .16], p < .01, direct effect; path c’: d = .07, 95% CI = [.00, .13], p > .01). 
Formal mediation analysis revealed a significant indirect effect of obesity on physiological dysregulation through weight discrimination (d = .02, 95% CI = [.01, .04], p < .01), as shown in Table 2. An examination of the effect ratio showed that the indirect effect of weight discrimination could account for 27% of the total effect of obesity on longitudinal changes in physiological dysregulation.

Robustness tests. Consistent with the main study results, weight discrimination explained 30% of the longitudinal association between a continuous BMI measure and increased physiological dysregulation over time (b = .010, 95% CI = [.004, .016], p < .01 reduced to b = .007 95% CI = [.00, .014], p > .01). Similarly, we found that weight discrimination explained a quarter of the longitudinal association between waist circumference and increased physiological dysregulation (b = .004, 95% CI = [.002, .007], p < .01 reduced to b = .003, 95% CI = [.00, .006], p > .01). As such, it appears that weight discrimination explains a similar portion of the link between initial adiposity and subsequent physiological dysregulation regardless of whether obesity status, continuous BMI, or waist circumference is used to measure adiposity in this sample. 
Next, we examined the role of gender. A similar proportion of males (12.3%) and females (13.6%) with obesity reported experiencing weight-based discrimination in this sample. The association between initial obesity and longitudinal change in physiological dysregulation was not moderated by gender (b = -.02, 95% CI = [-.16, .12], p > .01) nor was the association between perceived weight discrimination and changes in physiological dysregulation (b = .07, 95% CI = [-.25, .38], p > .01). These analyses suggest that there is little evidence that the key mediation paths examined differed markedly between males and females.  
In additional analyses, we showed that the relationship between weight discrimination and subsequent dysregulation was not substantially attenuated when more stringent controls for initial adiposity were introduced (model adjusted for obesity and covariates: d = .23, 95% CI = [.07, .40], p < .01; model adjusted for initial BMI, waist circumference, and covariates: d = .22, 95% CI = [.04, .40], p > .01).
 Finally, we assessed the association between perceived weight discrimination and longitudinal change in each biomarker variable. The point estimates for the linkages between weight discrimination and changes in biomarkers were positive in all cases, as shown in Table S5. Associations between weight discrimination and individual biomarkers were not, however, statistically significant. It therefore appears that a robust association between weight discrimination and changes in biological functioning is primarily evident when biomarker variables are examined in concert (d = .23, 95% CI = [.07, .40], p < .01), demonstrating the advantage of drawing on an integrated physiological dysregulation index to capture the physiological changes following weight discrimination. 

Discussion
Obesity is associated with an increased risk of early mortality and to date it has been largely assumed that the adverse effects obesity has on health are driven by the biological strain that excess body fat has on physiological systems that regulate cardiovascular and metabolic functioning. In this study we tested whether the widespread discrimination experienced by individuals living with obesity may play an important, but underappreciated, role in explaining why obesity is associated with the deterioration of healthy physiological functioning. Our study was designed to move beyond initial studies indicating that weight discrimination may in part explain cross-sectional obesity-related decrements in self-reported health (Jackson et al., 2015; Major & Hunger, 2015). 
Consistent with prior research (Kaan et al., 2006; Van Gaal, 2006), we found that obesity was associated with increases in physiological dysregulation over four years in a large sample of older English adults. Critically, this longitudinal association was accounted for in part by perceived weight discrimination; those with obesity were more likely to go on to report experiencing weight-based discrimination and these stigmatizing experiences predicted adverse changes in physiological dysregulation over time. Specifically, perceived weight discrimination was associated with a 0.23 SD increase in physiological dysregulation as gauged by cardiovascular, inflammatory, and lipid/metabolic dysregulation, and this accounted for 27% of the relation between obesity and subsequent increases in dysregulation. Importantly, these associations were observed after adjustment for initial sociodemographic characteristics, dysregulation levels, medication usage and health conditions.  
These findings are in line with prior cross-sectional research that has documented linkages between perceived weight-based discrimination and high levels of clinical indicators of ill health, such as C-reactive protein and glycated haemoglobin (Sutin et al., 2014; Potter et al., 2015). Our longitudinal findings show that these relations may reflect the direction of influence from weight discrimination to inflammation and glucose metabolism. Previously, a single longitudinal study has linked initial weight discrimination to raised levels of physiological dysregulation measured 10 years later (Vadiveloo & Mattei, 2017). This study was hampered by the absence of objective measures of obesity and physiological dysregulation at baseline. The current study provides the first prospective evidence of an association between perceived weight discrimination and longitudinal changes in physiological dysregulation, as measured using objectively measured clinical indicators of health status. We suggest that the cumulative toll of these alterations in biological processes could account for part of the recently documented association between weight discrimination and premature mortality (Seeman et al., 2001; Sutin et al., 2015). Our mediation findings also provide the first longitudinal evidence that directly implicates weight-based discrimination as a channel through which obesity generates long-run detrimental biological effects across a range of physiological parameters.
We suggested that these consequential health effects may occur because weight-based social stigmatization acts as an interpersonal stressor that can set in motion a cycle of daily stress, negative affect, and maladaptive coping responses (Schvey et al., 2014; Sutin et al., 2016a; Sutin et al., 2016b; Vartanian & Porter, 2016). Such stress-related responses could influence physiological dysregulation directly through biological mechanisms (Epel et al., 2001; Jackson et al., 2016) or act indirectly by impairing weight management (Tomiyama, 2014). For example, those experiencing weight stigma fear negative evaluation from other people and report overeating and reduced motivation to engage in exercise, which could hamper weight control (Vartanian & Shaprow, 2008; Vartanian & Porter, 2016). Perceived weight discrimination could also contribute to adverse health effects by impeding chronic illness management. For example, community-dwelling adults with diabetes who report experiencing weight-based discrimination have shown poor diabetes self-care in key areas (i.e. diet, physical activity, blood glucose monitoring) and also impaired glycemic control (Potter et al., 2015). 
Further research is now needed to articulate the behavioral and biological pathways though which unfair treatment based on body weight may contribute to physiological dysregulation and help explain the obesity-related disease burden. This work could help inform the development of interventions that aim to promote adaptive coping responses and ‘inoculate’ those with obesity against the harmful effects of weight-based stigma and discrimination. Regardless of the precise pathways linking weight discrimination to health, the current findings highlight the importance of developing stigma prevention policies including informing the public that the denigration of people with obesity may have damaging health consequences (Tomiyama et al., 2018). Our findings suggest that intervention strategies that are successful in reducing the stigmatization of obesity (Pearl, 2018) may also act to reduce the physiological consequences and disease-burden of obesity. 
Whilst we identified evidence that the social experience of body weight may partially explain the biomedical consequences of obesity, our investigation was limited in several respects. First, we focused on middle and older aged adults, and further work is now needed to test whether this process may be observed in younger adults. Obesity may be stigmatised most among younger individuals (Hebl, Ruggs, Singletary, & Beal, 2008) and weight-based discrimination has been linked to distress, maladaptive health behaviors, and poor health in young adults (Pearl, 2018; Puhl & Heuer, 2009). As such, it is feasible that weight discrimination may play a similar role in explaining the health effects of obesity in younger samples. Second, our sample identified predominantly as white, so research drawing on more racially diverse samples is needed to decipher whether the study findings extend to other ethnic groups. Third, our measure of weight discrimination assessed whether or not participants reported everyday experiences of discrimination at a single time-point. Administering longer-form measures at multiple time-points would increase the reliability of the assessment and help ensure estimates of the indirect effect of weight discrimination were not attenuated by measurement error. Finally, perceived weight discrimination is part of a broader constellation of related psychosocial constructs (e.g. perceived weight, weight stigma concerns, weight bias internalization) that may combine to mediate the pathway from obesity to physiological dysregulation (Daly et al., 2017; Hunger & Major, 2015). For instance, a recent study suggests that the tendency of those with obesity to self-stigmatize by internalizing weight bias may also contribute to greater cardiometabolic risk among people with obesity (Pearl et al., 2017). Future research may seek to investigate this pathway more extensively. 
Conclusions
In a large sample of English adults, weight-based discrimination predicted increases in physiological dysregulation over time and partly explained the longitudinal association between obesity and cardiovascular, metabolic, and immune function. These findings provide initial evidence that the psychosocial strain of weight stigma may account for a notable proportion of the obesity-related disease burden.



















References

Andreyeva, T., Puhl, R.M., & Brownell, K.D. (2008). Changes in perceived weight discrimination among Americans, 1995–1996 through 2004–2006. Obesity, 16, 1129-1134.
Craig, R., Deverill, C., & Pickering, K. (2006). Quality control of blood, saliva and urine analytes. In K., Sproston, & J., Mindell (Eds.), Health survey for England 2004: Methodology and documentation (pp. 34-41). Leeds: The Information Centre. 
Daly, M., Robinson, E., & Sutin, A.R. (2017). Does knowing hurt? Perceiving oneself as overweight predicts future physical health and well-being. Psychological Science, 28, 872-881.
Epel, E., Lapidus, R., McEwen, B., & Brownell, K. (2001). Stress may add bite to appetite in women: a laboratory study of stress-induced cortisol and eating behavior. Psychoneuroendocrinology, 26, 37-49.
GBD 2015 Obesity Collaborators. (2017). Health effects of overweight and obesity in 195 countries over 25 years. New England Journal of Medicine, 377, 13-27.
Guh, D.P., Zhang, W., Bansback, N., Amarsi, Z., Birmingham, C.L., & Anis, A.H. (2009). The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health, 9, 88.
Hampson, S.E., Goldberg, L.R., Vogt, T.M., Hillier, T.A., & Dubanoski, J.P. (2009). Using physiological dysregulation to assess global health status: Associations with self-rated health and health behaviors. Journal of Health Psychology, 14, 232-241.
Hatzenbuehler, M.L., Keyes, K.M., & Hasin, D.S. (2009). Associations between perceived weight discrimination and the prevalence of psychiatric disorders in the general population. Obesity, 17, 2033-2039.
Hebl, M. R., Ruggs, E. N., Singletary, S. L., & Beal, D. J. (2008). Perceptions of obesity across the lifespan. Obesity, 16(Suppl. 2), S46-S52. 
Himmelstein, M.S., Incollingo Belsky, A.C., & Tomiyama, A.J. (2015). The weight of stigma: Cortisol reactivity to manipulated weight stigma. Obesity, 23, 368-374.
Hunger, J.M., & Major, B. (2015). Weight stigma mediates the association between BMI and self-reported health. Health Psychology, 34, 172-175.
Jackson, S. E., Beeken, R. J., & Wardle, J. (2015). Obesity, perceived weight discrimination, and psychological well‐being in older adults in England. Obesity, 23, 1105-1111.
Jackson, S.E., Kirschbaum, C., & Steptoe, A. (2016). Perceived weight discrimination and chronic biochemical stress: A population‐based study using cortisol in scalp hair. Obesity, 24, 2515-2521.
Juster, R. P., McEwen, B. S., & Lupien, S. J. (2010). Allostatic load biomarkers of chronic stress and impact on health and cognition. Neuroscience & Biobehavioral Reviews, 35, 2-16.
Kahn, S.E., Hull, R.L., & Utzschneider, K.M. (2006). Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature, 444, 840-846.
Major, B., Eliezer, D., & Rieck, H. (2012). The psychological weight of weight stigma. Social Psychological and Personality Science, 3, 651-658.
Pascoe, E.A., & Smart Richman, L. (2009). Perceived discrimination and health: a meta-analytic review. Psychological Bulletin, 135, 531-554.
Pearl, R.L. (2018). Weight bias and stigma: public health implications and structural solutions. Social Issues and Policy Review, 12, 146-182.
Pearl, R. L., Wadden, T. A., Hopkins, C. M., Shaw, J. A., Hayes, M. R., Bakizada, Z. M., ... Alamuddin, N. (2017). Association between weight bias internalization and metabolic syndrome among treatment‐seeking individuals with obesity. Obesity, 25, 317-322.
Potter, L., Wallston, K., Trief, P., Ulbrecht, J., Juth, V., & Smyth, J. (2015). Attributing discrimination to weight: associations with well-being, self-care, and disease status in patients with type 2 diabetes mellitus. Journal of Behavioral Medicine, 38,  863-875.
Puhl, R.M., & Heuer, C.A. (2009). The stigma of obesity: a review and update. Obesity, 17, 941-964.
Robinson, E., Sutin, A., & Daly, M. (2017). Perceived weight discrimination mediates the prospective relation between obesity and depressive symptoms in US and UK adults. Health Psychology, 36, 112-121.
Schafer, M.H., & Ferraro, K.F. (2011). The stigma of obesity: does perceived weight discrimination affect identity and physical health? Social Psychology Quarterly, 74, 76-97.
Schvey, N.A., Puhl, R.M., & Brownell, K.D. (2014). The stress of stigma: exploring the effect of weight stigma on cortisol reactivity. Psychosomatic Medicine, 76, 156-162.
Seeman, T.E., McEwen, B.S., Rowe, J.W., & Singer, B.H. (2001). Allostatic load as a marker of cumulative biological risk: MacArthur studies of successful aging. Proceedings of the National Academy of Sciences, 98, 4770-4775.
Seplaki, C. L., Goldman, N., Glei, D., & Weinstein, M. (2005). A comparative analysis of measurement approaches for physiological dysregulation in an older population. Experimental Gerontology, 40, 439–439.
Steptoe, A., Breeze, E., Banks, J., & Nazroo, J. (2012). Cohort profile: the English longitudinal study of ageing. International Journal of Epidemiology, 42, 1640-1648.
Streiner, D. L. (2003). Being inconsistent about consistency: When coefficient alpha does and doesn't matter. Journal of Personality Assessment, 80, 217-222.
Sutin, A., Robinson, E., Daly, M., & Terracciano, A. (2016a). Weight discrimination and unhealthy eating-related behaviors. Appetite, 102, 83-89.
Sutin, A.R., Stephan, Y., & Terracciano, A. (2015). Weight discrimination and risk of mortality. Psychological Science, 26, 1803-1811.
Sutin, A.R., Stephan, Y., Grzywacz, J.G., Robinson, E., Daly, M., & Terracciano, A.  (2016b). Perceived weight discrimination, changes in health, and daily stressors. Obesity, 24, 2202-2209.
Sutin, A.R., Stephan, Y., Luchetti, M., & Terracciano, A. (2014). Perceived weight discrimination and C‐reactive protein. Obesity, 22, 1959-1961.
Tomiyama, A.J. (2014). Weight stigma is stressful. A review of evidence for the cyclic obesity/weight-based stigma model. Appetite, 8, 8-15.
Tomiyama, A. J., Carr, D., Granberg, E. M., Major, B., Robinson, E., Sutin, A. R., & Brewis, A. (2018). How and why weight stigma drives the obesity ‘epidemic’and harms health. BMC Medicine, 16, 123. https://doi.org/10.1186/s12916-018-1116-5
Turvey, C. L., Wallace, R. B., & Herzog, R. (1999). A revised CES-D measure of depressive symptoms and a DSM-based measure of major depressive episodes in the elderly. International Psychogeriatrics, 11, 139 –148.
Vadiveloo, M., & Mattei, J. (2017). Perceived weight discrimination and 10-year risk of allostatic load among US adults. Annals of Behavioral Medicine, 51, 94-104.
Van Gaal, L.F., Mertens, I.L., & De Block, C.E. (2006). Mechanisms linking obesity with cardiovascular disease. Nature, 444, 875-880.
Vartanian, L.R., & Porter, A.M. (2016). Weight stigma and eating behavior: A review of the literature. Appetite, 102, 3-14.
Vartanian, L.R., & Shaprow, J.G. (2008). Effects of weight stigma on exercise motivation and behavior: a preliminary investigation among college-aged females. Journal of Health Psychology, 13, 131-138.
Williams, D.R., Yu, Y., Jackson, J.S., & Anderson, N.B. (1997). Racial differences in physical and mental health: Socio-economic status, stress and discrimination. Journal of Health Psychology, 2, 335-351.





Declaration of Conflicting Interests
The authors declared that they had no conflicts of interest with respect to their authorship or the publication of this article.

Funding
This research received no external funding. ER’s salary is in part funded by the ESRC and MRC and ER has previously received research funding from Unilever and the American Beverage Association. ARS was supported by a grant from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (1R15HD083947).

Contributions/Acknowledgements 
All the authors developed the study concept and were responsible for the study design.          M. Daly performed the data analysis and drafted the manuscript, and E. Robinson and A. R. Sutin provided critical revisions. All the authors approved the final version of the manuscript for submission.









Table 1. 
Basic Demographic Characteristics and Descriptive Statistics for Participants. 
	Full sample(N = 3,609)	Obese                   (N = 1,122)	Non-obese(N = 2,487)
Variable		   M(SD) / %	M(SD) / %	M(SD) / %
Age (years)	64.78 (9.24)	64.26 (8.94)	65.03 (9.36)
Female (%)	52.7	56.8	50.8
White (%)	96.2	96.3	96.2
Degree (%)	16.0	12.2	17.8
Wealth quintilea	3.07 (1.37)	2.77 (1.31)	3.21 (1.37)
BMI baseline (kg/m2)	28.22 (5.05)	34.07 (4.10)	25.60 (2.68)
Perceived weight discrimination (%)	4.6	13.0	0.8
a Net household wealth ranging from 1 = lowest quintile to 5 = highest quintile. 








Table 2. 
Mediation Model of the Indirect Effect of Obesity on Longitudinal Changes in Physiological Dysregulation through Weight Discrimination (N = 3,609). 
	Point Estimate	95% CI        Lower ; Upper	Effect ratio
   Obesity -> discriminationa      (IV to mediator, path a) 	18.90**	 [9.92 ;  	35.99]	
   Discrimination -> dysregulationb      (mediator to DV, path b)	.23**	  [.07   ; 	.40]	
   Obesity -> dysregulationb       (total effect, path c)	.09**	  [.02   ; 	.16]	
   Obesity -> dysregulationb   (direct effect, path c’) 	     .07	  [.00   ;	.13]	
   Obesity -> dysregulatonb   (indirect effect)	.02**	  [.01   ;    .04]	.27
a Odds ratio from logistic regression model.
b Linear regression coefficient. 
Note.  95% confidence intervals and statistical significance levels are based on models using robust standard errors. Models use latent change in physiological dysregulation z-scores as the outcome variable. Models are adjusted for baseline physiological dysregulation, age, sex, ethnicity (white vs. other), degree qualification, household wealth, medication usage, chronic conditions, and depressive symptoms. 
**p<.01


Figure 1. Latent Change Score Model of the Mediation Channel from Obesity to Longitudinal Changes in Physiological Dysregulation (PHYS) through Perceived Weight Discrimination.
Note. Physiological dysregulation index (PHYS) variables at baseline (T1) and follow-up (T2) are constrained to be equal by fixing the autoregressive path to unity. The latent change score ( PHYS) factor loading is fixed to 1 to captures the residual variance in dysregulation at follow-up. The rate of change in dysregulation is denoted by ‘PHYS’ and variance in change by ‘2PHYS’. Covariates are omitted from the path diagram. 


Table S1.

Descriptive Statistics and Correlation Matrix for the Physiological Dysregulation Index and Individual Biomarker Variables at Baseline and Follow-Up.
	M (SD)	Physdys (T1)	Physdys (T2)	BP(T1)	BP(T2)	HR(T1)	HR(T2)	CRP(T1)	CRP(T2)	WB(T1)	WB(T2)	Trig (T1)	Trig  (T2)	Chol ratio (T1)	Chol ratio (T2)	Gluc(T1)	Gluc(T2)	HbA1c (T1)
Physiological dysregulation (T1)	-.01 (0.98)	1.00																
Physiological dysregulation (T2)	.01 (1.02)	0.68	1.00															
Blood pressure (T1)	103.6    (12.1)	0.40	0.25	1.00														
Blood pressure (T2)	103.1 (12.3)	0.21	0.35	0.50	1.00													
Heart rate (T1)	67.2 (10.7)	0.46	0.27	0.09	0.07	1.00												
Heart rate (T2)	66.4 (10.6)	0.29	0.47	0.11	0.08	0.55	1.00											
C-reactive protein (T1)	0.68 (1.11)	0.55	0.41	0.11	0.08	0.17	0.14	1.00										
C-reactive protein (T2)	0.56 (1.10)	0.36	0.54	0.09	0.07	0.11	0.20	0.61	1.00									
White blood cells (T1)	6.46  (1.93)	0.52	0.39	0.08	0.05	0.18	0.11	0.29	0.22	1.00								
White blood cells (T2)	6.61 (2.02)	0.37	0.54	0.07	0.06	0.10	0.18	0.22	0.29	0.63	1.00							
Triglyceride level (T1)	1.79 (1.06)	0.62	0.41	0.10	0.06	0.13	0.07	0.15	0.11	0.19	0.15	1.00						
Triglyceride level (T2)	1.52 (0.84)	0.44	0.59	0.08	0.07	0.05	0.12	0.17	0.13	0.15	0.19	0.61	1.00					
Cholesterol ratio (T1)	3.80 (1.02)	0.54	0.38	0.07	0.07	0.04	0.02	0.20	0.12	0.14	0.11	0.56	0.40	1.00				
Cholesterol ratio (T2)	3.53 (1.09)	0.38	0.51	0.03	0.06	0.03	0.05	0.16	0.17	0.12	0.10	0.42	0.61	0.72	1.00			
Glucose (T1)	4.93 (1.03)	0.49	0.23	0.08	0.04	0.07	0.05	0.10	0.05	-0.02	0.04	0.09	0.10	0.03	-0.01	1.00		
Glucose (T2)	5.43 (1.03)	0.28	0.55	0.07	0.01	0.04	0.09	0.10	0.11	0.10	0.08	0.09	0.13	0.04	0.03	0.47	1.00	
HbA1c (T1)	40.83 (7.2)	0.50	0.41	0.04	-0.04	0.12	0.11	0.15	0.10	0.16	0.16	0.18	0.16	0.05	0.02	0.57	0.46	1.00
HbA1c (T2)	41.6 (8.23)	0.41	0.52	0.03	-0.03	0.12	0.13	0.14	0.15	0.14	0.18	0.17	0.20	0.04	0.04	0.43	0.57	0.79




























Note: Correlations greater than 0.05 are statistically significant at the p < .01 level. 
Physiological dysregulation measures are derived from eight standardized biomarkers and the measures are standardized to have a mean of 0 and SD of one across waves. Blood pressure (BP) is derived from the mean of systolic and diastolic blood pressure (mmHg). Heart rate (HR) is measured in beats per minute. C-reactive protein (CRP) is the natural logarithm of CRP measured in mg/L. White blood cell count (WB) is measured in 10^9 cells/L. Triglyceride level (Trig) is measured in mmol/L. The cholesterol ratio is the ratio of total to HDL cholesterol (both measured in mmol/L). Glucose (Gluc) is measured in mmol/L and glycated haemoglobin (HbA1c) is measured in mmol/mol. 

Table S2.
Diagnoses of Chronic Conditions and Medication Usage for ELSA Participants. 
	Full sample(N = 3,609)	Obese                   (N = 1,122)	Non-obese(N = 2,487)
Variable		            %	%	%
High blood pressure	39.4	51.6	33.9
Angina	8.4	11.2	7.1
Congestive heart failure	0.6	1.5	0.2
Myocardial infarction	4.9	6.1	4.3
Arrhythmia 	7.0	7.6	6.7
Heart murmur	3.9	4.3	3.7
Stroke	3.2	3.8	2.9
Diabetes or high blood sugar	8.8	15.1	6.0
High cholesterol	35.0	39.7	32.8
Lung disease	5.9	5.9	5.9
Asthma	13.2	16.4	11.7
Arthritis	36.6	46.4	32.1
Osteoporosis	7.7	8.4	7.4
Cancer	7.6	7.8	7.5
Psychiatric condition	10.3	11.2	9.9
Glaucoma	5.9	5.4	6.1
Diabetic retinopathy	1.7	3.3	1.0
Macular degeneration	3.3	3.0	3.5
Cataracts	18.5	19.5	18.1
Blood pressure medication	29.0	38.8	24.6
Injecting insulin	1.7	3.0	1.1
Diabetes medication	5.8	10.4	3.7
Cholesterol lowering medication 	20.6	26.5	18.0
Cholesterol medication (prophylactic use)	1.6	2.0	1.5





Table S3.

Correlation Matrix for Obesity, Weight Discrimination, the Physiological Dysregulation Index, and Covariates.

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18
1. Obesity	1.00																	
2. Weight discrimination	0.27	1.00																
3. Physiol. dysreg. (T1)	0.33	0.15	1.00															
4. Physiol. dysreg. (T2)	0.27	0.16	0.68	1.00														
5. Age	-0.04	-0.11	0.03	0.04	1.00													
6. Female	0.06	0.02	-0.08	-0.07	0.06	1.00												
7. White	0.00	-0.06	-0.09	-0.02	0.02	0.07	1.00											
8. Degree	-0.07	0.00	-0.09	-0.09	-0.14	-0.13	-0.04	1.00										
9. Wealth	-0.15	-0.09	-0.19	-0.20	-0.11	-0.05	0.02	0.25	1.00									
10. High blood pressure	0.17	0.06	0.16	0.16	0.22	-0.02	-0.01	-0.07	-0.13	1.00								
11. Angina	0.07	0.04	0.03	0.05	0.23	-0.05	0.01	-0.05	-0.13	0.18	1.00							
12. Heart failure	0.08	0.02	0.16	0.08	0.00	-0.01	-0.09	0.02	-0.03	0.05	0.13	1.00						
13. Myocardial infarc.	0.04	0.00	-0.01	0.03	0.18	-0.05	0.03	-0.05	-0.09	0.14	0.40	0.11	1.00					
14. Arrhythmia	0.02	-0.02	-0.01	0.00	0.13	0.02	0.03	0.02	-0.03	0.09	0.11	0.09	0.11	1.00				
15. Heart murmur	0.02	0.00	-0.01	-0.01	0.12	0.07	0.03	-0.01	-0.04	0.11	0.11	0.06	0.14	0.15	1.00			
16. Diabetes 	0.15	0.08	0.24	0.27	0.09	-0.05	-0.03	0.00	-0.11	0.22	0.16	0.11	0.16	0.03	0.04	1.00		
17. Stroke	0.02	0.01	0.01	0.02	0.15	0.02	0.04	-0.04	-0.10	0.13	0.11	0.00	0.11	0.09	0.11	0.06	1.00	
18 High cholesterol	0.07	0.04	0.06	0.08	0.13	0.05	0.04	-0.08	-0.05	0.26	0.16	0.00	0.09	0.05	0.06	0.13	0.13	1.00
19. Lung disease	0.00	0.05	0.04	0.07	0.06	-0.02	0.01	-0.04	-0.12	0.06	0.10	0.02	0.06	0.03	0.06	0.02	0.02	0.06
20. Asthma	0.07	0.05	0.07	0.06	0.01	0.06	0.01	0.01	-0.07	0.02	-0.01	-0.02	-0.03	0.05	0.03	0.00	0.05	0.04
21. Arthritis	0.14	0.06	0.07	0.08	0.18	0.18	0.01	-0.09	-0.16	0.17	0.14	0.07	0.06	0.11	0.11	0.06	0.09	0.15
22. Osteoporosis	0.02	0.00	0.05	0.06	0.14	0.18	-0.03	-0.06	-0.07	0.05	0.11	0.09	0.10	0.06	0.09	0.00	0.06	0.06
23. Cancer	0.01	0.03	0.02	0.03	0.11	0.06	-0.02	-0.02	0.00	0.04	0.03	0.07	0.02	0.04	0.03	0.02	0.00	0.02
24. Psychiatric condition	0.02	0.06	0.03	0.04	-0.12	0.07	0.06	0.05	-0.06	0.03	0.02	0.02	-0.01	0.01	-0.01	0.00	-0.01	0.05
25. Glaucoma	-0.01	-0.01	0.00	0.01	0.16	-0.01	0.01	-0.03	-0.04	0.08	0.05	0.07	0.07	0.05	0.05	0.02	-0.01	0.06
26. Diabetic retinopathy	0.08	0.06	0.12	0.10	0.06	0.00	-0.01	0.00	-0.05	0.12	0.08	-0.01	0.08	0.07	0.03	0.36	0.11	0.09
27. Macular degen.	-0.01	-0.03	-0.03	0.00	0.19	0.01	0.04	0.00	-0.01	0.05	0.06	-0.02	0.02	0.04	0.05	0.02	0.02	-0.01
28. Cataracts	0.02	-0.03	0.04	0.04	0.48	0.09	0.00	-0.06	-0.05	0.15	0.17	0.02	0.14	0.08	0.07	0.09	0.12	0.10
29. Blood pressure med.	0.15	0.07	0.13	0.13	0.25	-0.04	-0.04	-0.07	-0.13	0.77	0.19	0.06	0.10	0.08	0.08	0.22	0.14	0.24
30. Injecting insulin	0.07	0.06	0.20	0.13	0.04	-0.01	-0.08	0.00	-0.04	0.10	0.13	0.15	0.08	0.05	0.00	0.39	0.11	0.06
31. Diabetes medication	0.14	0.09	0.24	0.24	0.05	-0.05	-0.05	0.00	-0.09	0.15	0.09	0.11	0.07	0.01	-0.01	0.77	0.07	0.11
32. Cholesterol med.a	0.10	0.04	0.06	0.08	0.14	0.03	0.01	-0.08	-0.09	0.26	0.20	0.01	0.11	0.04	0.07	0.18	0.15	0.68
33. Cholesterol med.b	0.02	-0.01	0.02	0.05	0.05	-0.02	0.01	0.00	-0.03	0.05	0.07	-0.01	0.06	0.02	0.04	0.11	-0.01	0.17
34. Depressive symp.	0.08	0.16	0.11	0.14	0.03	0.19	0.01	-0.11	-0.27	0.09	0.09	0.04	0.09	0.06	0.05	0.08	0.04	0.11
a Cholesterol lowering medication. 
b Cholesterol medication (prophylactic use)



Table S3 (continued).

Correlation Matrix for Obesity, Weight Discrimination, Physiological Dysregulation Index, and Covariates.

	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33
19. Lung disease	1.00														
20. Asthma	0.14	1.00													
21. Arthritis	0.08	0.07	1.00												
22. Osteoporosis	0.10	0.09	0.16	1.00											
23. Cancer	0.06	0.04	0.03	0.11	1.00										
24. Psychiatric condition	0.05	0.09	0.07	0.04	-0.01	1.00									
25. Glaucoma	0.08	-0.02	0.08	0.06	0.05	-0.02	1.00								
26. Diabetic retinopathy	0.00	-0.01	0.05	0.00	0.01	-0.01	0.08	1.00							
27. Macular degen.	-0.02	0.01	0.06	0.00	0.06	-0.03	0.06	0.06	1.00						
28. Cataracts	0.06	0.03	0.14	0.13	0.05	-0.06	0.19	0.06	0.16	1.00					
29. Blood pressure med.	0.03	0.01	0.14	0.01	0.04	-0.01	0.07	0.12	0.05	0.15	1.00				
30. Injecting insulin	-0.01	-0.01	0.00	0.03	0.04	-0.02	0.02	0.47	-0.01	0.06	0.10	1.00			
31. Diabetes medication	0.01	0.01	0.03	0.00	0.01	-0.01	-0.03	0.35	-0.02	0.06	0.18	0.41	1.00		
32. Cholesterol med.a	0.05	0.04	0.14	0.06	0.02	0.02	0.04	0.13	0.01	0.10	0.30	0.10	0.18	1.00	
33. Cholesterol med.b	0.01	0.04	0.05	0.01	0.01	-0.01	0.00	0.01	-0.02	0.01	0.04	0.03	0.08	-0.07	1.00
34. Depressive symp.	0.14	0.07	0.19	0.11	0.06	0.20	0.05	0.04	0.00	0.08	0.09	0.04	0.05	0.10	0.02
a Cholesterol lowering medication. 
b Cholesterol medication (prophylactic use)




Table S4.
Association between Perceived Weight Discrimination and Longitudinal Changes in Individual Biomarker Outcomes. 
		d	     95% CI       Lower ; Upper
  Blood pressure		.13	  [-.04 ;  	 .30]
  Heart rate  C-reactive protein		.07.16	[-.12 ;[.00 ;	 .25] .32]
  White blood cell count  Triglycerides		.04.20	[-.12 ;[.01 ;	 .20] .39]
  Total cholesterol to HDL ratio   Glucose		     .10     .07	[-.10 ;[-.20;	 .29] .33]
   Glycated hemoglobin		.15	  [-.15;       .45]
Note.  95% confidence intervals are based on models using robust standard errors. Associations are not statistically significant after correction for multiple comparisons.  Models use latent change in biomarker z-scores as outcome variables. Models are adjusted for baseline biomarker levels, age, sex, ethnicity (white vs. other), degree qualification, household wealth, medication usage, chronic conditions, and depressive symptoms. 
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